NCT02055300View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics Study of LY03005

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Major Depressive Disorder
Interventions
DRUG

LY03005

DRUG

Placebo

OTHER

Meal

DRUG

Pristiq

Trial Locations (1)

45227

Medpace, Cincinnati

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT02055300 - Safety, Tolerability and Pharmacokinetics Study of LY03005 | Biotech Hunter | Biotech Hunter